Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune... (the subjects maintained positive CD8+ T-...)

HOME >> MEDICINE >> TECHNOLOGY

Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses

Date:9/14/2011

the subjects maintained positive CD8+ T-cell responses out to six months.

Compared to the previously conducted HVTN 070 Phase I study, which assessed PENNVAX™-B with cytokine adjuvant IL-12 at double the dose, with four vaccinations, but without electroporation delivery, response rates in HVTN 080 with electroporation were significantly higher for both CD4+ responses (40.7%) and CD8+ T cell responses (3.6%).

Samples from eight placebo recipients and pre-vaccine samples from vaccine recipients were also tested and were negative for both CD4+ T-cell responses and CD8+ T-cell responses.

PENNVAX™-B delivered using the CELLECTRA® intramuscular electroporation delivery device with or without IL-12 was safe and generally well tolerated. There were no vaccine-related serious adverse events. Reported adverse events and injection site reactions were mild to moderate and required no treatment.

Dr. J. Joseph Kim, Inovio's President and CEO, said: "We are excited by the final results of the HVTN-080 study. These data are consistent with the previously announced interim results and unequivocally demonstrate the impact electroporation has on improving the immune potency of DNA vaccination. We appreciate the close collaboration with the NIH DAIDS and HVTN groups to systematically evaluate the immunogenicity of DNA immunogens together with cytokine adjuvants and delivery systems. We look forward to a continuing fruitful partnership with the HVTN and the DAIDS/NIH to further develop our HIV vaccine products to the next level."

About the HVTNThe HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center in Seattle, Wash., is an international collaboration of scientists and educators searching for an effective and safe HIV vaccine. The HVTN's mission is to facilitate the process of testing preventive vaccines against HIV/AIDS. The HVTN conducts all phases of clinical trials, from evaluating
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/20/2013)... MINNEAPOLIS , May 20, 2013 Uroplasty, Inc. ... will release financial results for the fiscal fourth quarter ... market close on Thursday, May 30, 2013. The Company ... these results on Thursday, May 30, 2013 at 4:30 ... to participate in the conference call should dial 888-549-7750, ...

(Date:5/20/2013)... Quebec , May 20, 2013 Valeant Pharmaceuticals International, ... members of its senior management team will make a presentation ... on Tuesday, June 11, 2013 at 9:20 a.m. PT. The ... Los Angeles, CA. A live ... on the company,s Web site at www.valeant.com . Click ...

(Date:5/20/2013)... 20, 2013 /PRNewswire-iReach/ -- Today at American Society ... Christine Ginocchio discussed Specific Technologies blood ... identification of microorganisms producing bloodstream infection. Dr. Ginocchio ... the Division of Infectious Disease Diagnostics at North ... non-sectarian health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ...

Breaking Medicine Technology:Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 2 Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2 Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3

[0] Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 [0] Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference [0] Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio

... IDM Pharma, Inc.,(the Company) (Nasdaq: IDMI ) ... clinical protocol finalized with the U.S. Food and ... osteosarcoma patients through a compassionate access study., ... increasing number of,requests for compassionate access to L-MTP-PE," ...

... not the Only Way We Suffer - ... Allergies Impact Mood and Self-Perception, KENILWORTH, N.J. and ... about 50,million people in the United States.(1)(2) Yet, according to ... a nuisance: in today,s society allergies get little respect.,As a ...

Cached Medicine Technology:IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 2 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 3 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 4 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 5 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 2 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 3 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 4 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 5 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 6 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 7

IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly

(Date:5/20/2013)... Mombo from Comfort & Harmony ... US Lactation Consultant Association (USLCA) May 2nd – 5th. ... other health professionals. , The USLCA annual conference ... discover and learn about the latest trends in lactation. ... nursing pillows, which new mothers use to help support ...

(Date:5/20/2013)... (PRWEB) May 21, 2013 People are so ... Stress levels are through the roof and are contributing ... handle this stress could mean the difference between life and ... Begin’ event on 29 May will share valuable, practical tools ... and influence the world around them for social good. , ...

(Date:5/20/2013)... According to a May 6, 2013 CBS News ... tanning salons in the US may soon have ... wants to see cancer warnings on indoor tanning beds ... eighteen for the use of indoor tanning and sun beds. ... become increasingly common over the last few decades (Go to ...

(Date:5/20/2013)... MI (PRWEB) May 20, 2013 ... Lupus Foundation will be holding ... in Lansing on June 10th. ... June 10th, 6:30 p.m. – ... Building (Across from Sparrow Hospital), ...

(Date:5/20/2013)... to a June 2009 Bloomberg article, it is estimated ... $3.6 billion dollars per year (i). Additionally, in ... 15 million incidents of medical harm each year (ii). ... any form of medical treatment should be aware of ... as “a dereliction of professional duty or a failure ...

Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2 Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2 Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2 Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2

[0] Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference [0] Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney [0] Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs [0] Lupus Support Group Meeting in Lansing on June 10th [0] Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases

... OF MICHIGAN URGES DETROIT EMPLOYERS TO SEE INFLUENZA AS ... in billions of dollars in lost wages every year, ... missed workdays a year, and about 200 million days ... Yet vaccination rates remain alarmingly low, especially among working ...

... and continued positive cash flow from operationsBOSTON, Feb. ... ), a leader in radiology and medical image ... results for the fourth quarter and year ended ... Q4 Financial Highlights Revenue : Total revenue ...

... - Conference call on Thursday, February 26, 2009, at 9:00 ... International (NYSE: SCI ), a leading provider of ... quarter and fiscal year 2008 and provided its comments on ... statements can be found at the end of this press ...

... Pharmaceuticals to increase access to radiological threat antidoteWASHINGTON, ... agreement in principle with Fleming Pharmaceuticals for the ... ThyroShield(R) Potassium Iodide Oral Solution is a ready-to-use, ... at risk of exposure to radioactive iodine. It ...

... Feb. 25 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... live webcast on Tuesday, March 3, 2009 at 9:00 am EST ... 31, 2008. The Company will release results after the market ... be available on the Par website at www.parpharm.com .Access to ...

... growing twice as fast as San Diego.The system rewards physicians ... Feb. 25 The cost of providing health care to ... as in San Diego, and Medicare now spends nearly three ... it does in Honolulu. This illustrates how huge inefficiencies in ...

Influenza Infection Costs Employers Billions Each Year; Working Adults Largest Group Not Immunized Annually AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 Service Corporation International Announces Fourth Quarter 2008 Financial Results and Comments on Outlook for 2009 Heyltex Corporation to Become Exclusive Distributor of ThyroShield(R)Par Pharmaceutical to Host Fourth Quarter and Full Year 2008 Results Conference Call on March 3 at 9:00 am Taming Wide Variations in Spending Key to Health Reform - New England Journal of Medicine Commentary from Dartmouth Atlas Project

... membrane parasite soluble lysate ... as antigen. Since this ... than the recombinant kit, ... use two ELISA techniques ...

The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....

... The dual-electrode SPL defibrillator lead ... design, offering the flexibility and ... Designed for the physician who ... shocking coils, the SPL lead ...

... The Medtronic Subcutaneous Lead ... implanted subcutaneously with the use ... Model 6996T. Improved SQ design ... DFTs, a fast and easy ...

Medicine Products:

Chagatest ELISA T. cruzi IgG CELISA SPL™ Leads Subcutaneous Lead System Model 6996SQ